A practical reference on amino acid sequence: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-20 and is reviewed periodically as new material appears.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
== Distribution and habitat == Clown loaches are native to the islands of Sumatra and Borneo in Indonesia. Clear stream environments provide the optimal habitat for clown loaches, but biannual monsoon flooding forces the fish to move into flooded flood plains, or murky or blackwater rivers or lakes, for 7–8 months of the year, and clown loaches are commonly found in the flood plains of hilly areas. Breeding adults migrate to smaller waterways to spawn annually. In its native habitat, the fish is found in water with a temperature range of 25 to 30 °C (77 to 86 °F), a pH between 5.0 and 8.0, and water hardness between 5 and 12 dH.
== Goals == The project aims to develop both the methodology and hardware to allow communities and individuals to produce medical-grade insulin for the treatment of diabetes. These methods will be low-cost in order to combat the high price of insulin in places like the US. There is also potential for small-scale distributed production that may allow for improved insulin access in places with poor availability infrastructure. Access to insulin remains so insufficient around the globe that "half of all people who need insulin lack the financial or logistical means to obtain adequate supplies".
== Features == Copper-catalyzed allylic substitutions are characterized by their unique regioselectivity compared to other transition-metal-catalyzed allylic substitutions, the most well-known being the palladium-catalyzed Tsuji-Trost reaction. The distinct mechanism of copper-catalyzed allylic substitutions has been known to provide high regioselectivity of the γ substituted product, compared to the α substituted isomer. The copper catalyst used can be symmetrical with two identical R groups, or with two different ligands. These reactions typically utilize “hard” carbon nucleophiles such as Grignard, diorganozinc, organolithium, and trialkyl aluminum reagents. This contrasts palladium-catalyzed allylic substitutions which involve “soft” nucleophiles..
=== ELISA === Enzyme-linked immunosorbent assay (ELISA) uses antigen-coated microtitre plates for the detection of ANAs. Each well of a microtitre plate is coated with either a single antigen or multiple antigens to detect specific antibodies or to screen for ANAs, respectively. The antigens are either from cell extracts or recombinant. Blood serum is incubated in the wells of the plate and is washed out. If antibodies that bind to antigen are present then they will remain after washing. A secondary anti-human antibody conjugated to an enzyme such as horseradish peroxidase is added. The enzyme reaction will produce a change in colour of the solution that is proportional to the amount of antibody bound to the antigen. There are significant differences in the detection of ANA by immunofluorescence and different ELISA kits and there is only a marginal agreement between these. A clinician must be familiar with the differences in order to evaluate the outcomes of the various assays.
The assistance of another person in retaining, controlling or using the benefits of drug dealing or criminal conduct under an arrangement (whether by concealment, removal from jurisdiction, transfer to nominees or otherwise) [section 43(1)/44(1)]. The concealment, conversion, transfer or removal from the jurisdiction, or the acquisition, possession or use of benefits of drug dealing or criminal conduct [section 46(1)/47(1)]. The concealment, conversion, transfer or removal from the jurisdiction of another person's benefits of drug dealing or criminal conduct [section 46(2)/47(2)]. The acquirement, possession or use of another person's benefits of drug dealing or criminal conduct [section 46(3)/47(3)].
Sources: en.wikipedia.org
=== Pharmacokinetics === The bioavailability of quercetin in humans after oral intake is very low, with one study concluding it must be less than 1%. Intravenous injection of quercetin shows a rapid decay in concentration described by a two-compartment model (initial half-life of 8.8 minutes, terminal half-life of 2.4 hours). Because it undergoes rapid and extensive metabolism, the biological effects presumed from in vitro studies are unlikely to apply in vivo. Quercetin supplements in the aglycone form are less bioavailable than the quercetin glycoside often found in foods, especially red onions. Ingestion with high-fat foods may increase bioavailability compared to ingestion with low-fat foods, and carbohydrate-rich foods may increase absorption of quercetin by stimulating gastrointestinal motility and colonic fermentation. Whereas quercetin has been shown to be a potent anti-inflammatory compound in a variety of in vitro and in vivo bioassay models, oral quercetin in human subjects has not exhibited the desired effects. Because of low solubility and poor bioavailability of quercetin, derivatives have been synthesized to overcome these challenges and enhance its biological activity, leading to compounds with improved properties for possible therapeutic applications.
Persistent muscle soreness Persistent fatigue, different from just being tired from a hard training session—occurs when fatigue continues even after adequate rest "Central fatigue can take the form of losing the desire or motivation to continue exercise or a decline in some aspect of the motor skills associated with continued exercise" Elevated resting heart rate – a persistently high heart-rate after adequate rest, such as in the morning after sleep, can indicate overtraining Reduced heart rate variability Increased susceptibility to infections Increased incidence of injuries Irritability Depression Burnout "Symptoms of overtraining include muscle soreness, boredom, poor motivation, sleep problems, increased morning pulse rate, diminished sex drive, a drop in energy, decreased resistance to illness, poor appetite and weight loss." There is a difference between overtraining and overreaching; overreaching is when an athlete is undergoing hard training but with adequate recovery; overtraining, however, is when an athlete is undergoing hard training without proper recovery. With over-reaching, the consequential drop in performance can be resolved in a few days or weeks.
January 23: Law granting an additional benefit to pregnant women already receiving allowances under the law of August 5, 1914. June 18: Law amending the law of April 7, 1915, authorizing the government to revoke naturalization decrees of former nationals of enemy countries: naturalized persons from a country at war with France can be stripped of French nationality, and this loss may extend to the wife and children depending on circumstances. July 27: Law establishing "Wards of the Nation"; women may hold positions in national and departmental offices. August 5: Law concerning breastfeeding in industrial and commercial establishments. October 1: Law on the repression of public drunkenness and regulation of drinking establishments; part of a campaign against clandestine prostitution by both women and men. Additionally, girls under 18 may no longer work in drinking establishments unless they are family members of the owner. 1919
== Calculation of CAL == CAL is measured in mm as the distance from the CEJ to the gingival margin (GM), using a periodontal probe. This provides an estimate of the true periodontal support and is used for monitoring changes in periodontal support over time. CAL is easily measured when CEJ is exposed / visible. CAL can also be calculated following the formula CAL (mm) = PPD (mm) + GR (mm) Calculation of CAL can be categorized into different clinical situations, depending on the position and level of the gingival margin.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.